Expand PHIO Menu
PHIO MENU

PHIO Latest Press Releases

-- March 16, 2026 --

Phio Pharmaceuticals Announces "A Groundbreaking Approach to Treating Skin Cancer" in a Fireside Chat with Force Family Office Newsfile 11:31 AM

-- March 13, 2026 --

Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing Globe Newswire 8:35 AM

-- March 10, 2026 --

Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th Globe Newswire 10:21 AM
Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDT Globe Newswire 7:59 AM
Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026, 11 AM EDT Newsfile 7:01 AM

-- March 5, 2026 --

Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update Newsfile 4:06 PM
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series Newsfile 7:01 AM

-- February 19, 2026 --

Phio Pharmaceuticals Aligns Leadership Team to Support Next Stage Development of PH-762 and Advancement of PH-894 Newsfile 7:01 AM

-- February 10, 2026 --

Phio Announces Safety Monitoring Committee's (SMC) Positive Wrap-up on Lead Clinical Candidate PH-762 in Skin Cancer Trial Newsfile 7:01 AM

-- January 26, 2026 --

Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference Newsfile 8:15 AM

-- January 23, 2026 --

DealFlow Discovery Conference Announces Initial Lineup of Presenting Companies Ahead of Next Week's Event ACCESS Newswire 2:51 PM

-- January 20, 2026 --

Phio Pharmaceuticals Announces Key Tumor Response Data from all Cohorts in Intratumoral PH-762 Dose Escalation Cutaneous Carcinoma Trial Newsfile 9:30 AM

-- January 15, 2026 --

Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference January 21-22, 2026 Newsfile 8:45 AM

-- December 23, 2025 --

Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762 Newsfile 8:46 AM

-- November 25, 2025 --

Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762 Newsfile 11:30 AM

-- November 17, 2025 --

Phio Pharmaceuticals Announces Upcoming Podium Presentation at the Advanced Therapies USA 2025 Congress Newsfile 8:45 AM

-- November 13, 2025 --

Phio Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update Newsfile 4:15 PM

-- November 7, 2025 --

Phio Pharmaceuticals to Present Recent Clinical Results from Skin Cancer Trial with siRNA based INTASYL PH-762 Newsfile 10:30 AM
Phio Pharmaceuticals Announces INTASYL PH-762 is Named Immunomodulatory Solution of the Year in the BioTech Breakthrough Award Program Newsfile 7:45 AM

-- November 3, 2025 --

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $13.4 Million Gross Proceeds Newsfile 1:53 PM
Phio Pharmaceuticals Announces Positive Pathology Results: Final Maximum Dose Cohort for INTASYL PH-762 Skin Cancer Trial Newsfile 7:45 AM

-- October 31, 2025 --

Phio Pharmaceuticals Announces Appointment of Mr. David H. Deming to the Position of Lead Independent Director Newsfile 10:15 AM
Market Data Delayed 15 Minutes